Aptinyx Inc
NASDAQ:APTX
Intrinsic Value
Aptinyx Inc. is a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
APTX
stock under the Base Case scenario is
1.736
USD.
Compared to the current market price of 0.096 USD,
Aptinyx Inc
is
Undervalued by 94%.
Aptinyx Inc's market capitalization is 6.5m USD.
APTX stock price is 0.096 USD.
APTX stock price (0.096 USD) is 94% less than its Intrinsic Value (1.736 USD).
APTX stock price (0.096 USD) is 97% less than its Relative Value (3.115 USD). Open Relative Valuation
APTX has upside potential of 421% compared to the average analyst price target.
Open Wall St Estimates
APTX's D/E (Debt to Equity) is equal to 1.11.
APTX's long-term assets (48m USD) exceed its long-term liabilties (30m USD).
APTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -37% to -138%, and is approaching profitability.
APTX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 122% to -1 896%, and is approaching profitability.
APTX has negative Operating Income for the last twelve months.
APTX has negative Net Income for the last twelve months.
APTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -138%.
APTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 896%.
APTX has negative Net Debt. This means that the company has more cash and short-term investments (45m USD) than debt (20m USD).
APTX has negative Free Cash Flow for the last twelve months.
APTX has negative three-year average ROE (Return on Equity): -66%. The company is not efficient at transforming stockholders' equity into net income.
APTX has negative three-year average ROIC (Return on Invested Capital): -1 206%. The company is not efficient at using invested capital to generate operating income.
APTX's short-term assets (48m USD) exceed its short-term liabilties (9m USD).
APTX's Altman Z-Score is very low and is equal to -15.26.
APTX doesn't generate enough operating income (-64m USD) to safely cover interest payments on its debt (3m USD).
Fundamental Analysis
Aptinyx Inc
Balance Sheet Decomposition
Aptinyx Inc
| Current Assets | 47.8m |
| Cash & Short-Term Investments | 44.6m |
| Other Current Assets | 3.2m |
| Non-Current Assets | 200k |
| Other Non-Current Assets | 200k |
| Current Liabilities | 9.3m |
| Accounts Payable | 1.4m |
| Accrued Liabilities | 400k |
| Other Current Liabilities | 7.5m |
| Non-Current Liabilities | 20.4m |
| Long-Term Debt | 20.4m |
Earnings Waterfall
Aptinyx Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-63.5m
USD
|
|
Operating Income
|
-63.5m
USD
|
|
Other Expenses
|
-2.6m
USD
|
|
Net Income
|
-66.1m
USD
|
Free Cash Flow Analysis
Aptinyx Inc
APTX Profitability Score
Profitability Due Diligence
Aptinyx Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Aptinyx Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
APTX Solvency Score
Solvency Due Diligence
Aptinyx Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Aptinyx Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APTX Price Targets Summary
Aptinyx Inc
According to Wall Street analysts, the average 1-year price target for
APTX
is 0.5 USD
.
Ownership
APTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
APTX Price
Aptinyx Inc
| Average Annual Return | -9.3% |
| Standard Deviation of Annual Returns | 9.4% |
| Max Drawdown | -99% |
| Market Capitalization | 6.5m USD |
| Shares Outstanding | 67 715 696 |
| Percentage of Shares Shorted | 3.93% |
Company Profile
Aptinyx Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aptinyx Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Evanston, Illinois and currently employs 40 full-time employees. The company went IPO on 2018-06-21. The firm has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which are focused on brain and nervous system functions. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and Lewy body dementia.
You don't have any saved screeners yet
